C ancer development is a multiple-step evolutionary process in which cancer cells acquire a selective advantage in their competition with neighboring cells [1] [2] [3] . With the advancement of high-throughput genomic characterization technologies, extensive studies have systematically elucidated the molecular basis of human cancers 4, 5 . One striking observation is the tremendous diversity of distinct molecular mechanisms among different cancer types, among different samples of the same cancer type, and even within a single tumor 6 . Regardless of the specific molecular changes occurring in each cancer, cancer cells must adapt to their microenvironment for rapid proliferation 6, 7 and metabolic adaptation is the key to this process 8, 9 . Indeed, metabolic reprogramming has been proposed as a hallmark of cancer cells 6, 7, 10 . However, quantitative characterization of metabolic adaptation at the cellular level remains challenging.
Amino acids (AAs), the building blocks of proteins, are an essential class of metabolites. As the composition of cellular biomass is dominated by proteins 11 , the regulation of protein synthesis and AA usage is particularly important for cancer cells, which have an enhanced demand for AAs to support their rapid growth 12, 13 . Mammalian cells can endogenously synthesize only 11 AAs, known as nonessential AAs (NEAAs) 14 and have to obtain the remaining 9 AAs, known as essential AAs (EAAs), from the diet 15 or microbes 16 . However, the endogenous synthesis of NEAAs might not be sufficient for the proliferation of cancer cells, as the reduced exogenous supply of NEAAs such as glutamine can impair the survival or tumorigenic potential of malignant cells 10, [17] [18] [19] . Importantly, recent metabolic profiling experiments have demonstrated that cancer cells obtain EAAs and some NEAAs from external sources for protein synthesis 11, 20 . Despite the importance of AAs to the proliferation of tumor cells, it remains unclear how the usage of AAs in protein synthesis affects cancer progression.
The use of different AAs in proteomes is presumably constrained by their biosynthetic energy cost, which varies greatly regarding the high-energy phosphate bonds consumed in biosynthesis in living organisms. In autotrophs (bacteria, yeast, and plants), which can synthesize all 20 proteinogenic AAs, biosynthetically inexpensive AAs are preferentially utilized over "expensive" AAs in the proteomes [21] [22] [23] [24] [25] [26] . The anticorrelation between the biosynthetic cost and usage (termed C-U anticorrelation hereafter) of AAs appears to be driven by natural selection for bioenergetic efficiency in the autotrophs 22 . Intriguingly, although animals can synthesize only 11 NEAAs 14 , significant C-U anticorrelations have been observed for all 20 AAs in humans and other animals when the cost of AA biosynthesis in bacteria 23, 24, 27 or yeast 28 is employed. A reasonable explanation is that EAAs and most NEAAs in animal cells are ultimately taken from the autotrophs in which the bioavailability of an AA is constrained by its biosynthetic cost 23, 24, 28 . Based on this hypothesis, the biosynthetic cost of AAs, combined with gene expression profiles, should well reflect how cells manage the expenditure of all 20 AAs in protein synthesis.
In this study, we introduce the concept of energy cost per AA for a gene (ECPA gene ) to measure the average biosynthetic cost of AAs in a gene/protein. Based on ECPA gene and the overall gene expression profile of a sample, we calculate ECPA cell , which is a quantitative index for the average biosynthetic cost of AAs in the proteomes of the cells. As the EAAs and most NEAAs in human cells are ultimately taken from the autotrophs, neither ECPA gene nor ECPA cell measures the actual energy human cells invest to synthesize the AAs endogenously. Instead, these parameters can be treated as the average price tag for the AAs in a protein or the proteome, respectively. Therefore, lower ECPA values indicate reduced relative usage of expensive AAs and vice versa. Using these two parameters, we investigate how cancer cells evolve to utilize AAs more economically by optimizing gene expression profiles.
Results
The biosynthetic cost underlies AA usage in human proteomes. Previous studies have demonstrated the C-U anticorrelation in a limited number of species (108 genomes 23 and 43 genomes 24 ). To test whether this is a general pattern, we examined the relationship between the biosynthetic cost and usage of AAs in 11,253 species spanning bacteria, archaea, protists, plants, fungi, invertebrates, and vertebrates (see Methods). Taking humans as an example, we counted the number of each AA in all the protein sequences ( Fig. 1a) and conducted a correlation analysis between the occurrence (log 2 ) of AAs and the biosynthetic cost (Supplementary Table 1 ) that was normalized by the AA decay rate as previously described 23 (Fig. 1b) . As expected 23, 24, 28 , we detected significant C-U anticorrelation using the biosynthetic costs of AAs in bacteria (B20, Pearson's r = − 0.89, P = 1.3 × 10 −7 ) or yeast (Y20, r = − 0.89, P = 1.8 × 10 −7 ) (Fig. 1b) . Our analyses in other species reveal that Pearson's r ranges from − 0.95 to − 0.5 (P < 0.05 in > 99% of the species), with a median value < − 0.8, suggesting that the C-U anticorrelation is universal across all seven clades. As the AA biosynthetic cost is highly conserved between bacteria (B20) and yeast (Y20, Supplementary Table 1) , in each species, the analyses with B20 and Y20 yielded nearly the same results (Fig.1b-d) .
Next, we questioned whether the C-U anticorrelation existed if we focused only on the 11 NEAAs that can be endogenously synthesized in human cells. As the biosynthetic pathway of NEAAs might be different in humans compared with yeast or bacteria 29 , we calculated the biosynthetic cost for each NEAA in humans (H11) following previous studies in bacteria 22 or yeast 21, 26 , while taking into account the differences (Supplementary Methods, Supplementary Table 1 and Supplementary  Figures 1-3) . We see that the relative costs for NEAAs are very similar among humans, bacteria, and yeast (Fig. 1e) , and still observe significant C-U anticorrelations in humans (Fig. 1b) and other animals ( Fig. 1c) with the H11 metric. It is not surprising that the correlations obtained with H11 are weaker than those obtained with B20 or Y20 (Fig. 1c, f) , as only 11 AAs were used in the analyses. We further confirmed the C-U anticorrelations in humans and five other species with permutation tests by randomly shuffling the cost (B20, Y20, or H11) of AAs 10,000 times and conducting correlation analysis ( Supplementary Fig. 4 ). Taken together, the universal C-U anticorrelation suggests that the biosynthetic cost underlies the usage of AAs not only in autotrophs but also in heterotrophs, such as humans.
Despite its prevalence, the C-U anticorrelation has not been verified with experimental data in autotrophs nor in heterotrophs. Herein, we provide evidence that the abundance of AAs hydrolyzed from proteomes of bacteria 30 or yeast 31 is significantly anticorrelated with the B20 or Y20 cost metric, respectively ( Supplementary Fig. 5a, 5b) . Moreover, the abundances of AAs hydrolyzed from proteins in whole bodies of rats, sheep, pigs, and chickens 32 show significant anticorrelations with the biosynthetic cost of all 20 AAs (B20 or Y20) or the 11 NEAAs (H11) (Pearson's r ≤ − 0.63, P < 0.05 in each test; Supplementary  Fig. 5c ). Our permutation analysis (Methods) further confirmed these patterns (Supplementary Table 2 ). To our knowledge, we provide the first experimental evidence that the biosynthetic cost governs the composition of AAs in proteomes of autotrophs and animals.
Human intracellular AAs come from two sources: (1) NEAAs endogenously synthesized in human cells or other animal cells (obtained through the food chain), both of which are shaped by the H11 cost metric, presumably due to metabolic efficiency; and (2) AAs ultimately taken from autotrophs, which are constrained by the B20 or Y20 cost metric. Although it is difficult to determine the relative contribution of each source to the total AAs, our simulations (Supplementary Methods) suggest that the mixtures of AAs from the two sources always yield significantly negative correlations between the overall abundance and cost of all 20 AAs in autotrophs ( Fig. 2a and Supplementary Fig. 6 ). Furthermore, the experimental data show that the cost is significantly anticorrelated with the abundance of free AAs in the livers of humans, chimpanzees, rhesus monkeys, and 459 (457) 131 (131) 156 (156) 639 (638) 203 (202) 176 (174) B20 Y20
9489 (9227) 459 (429) 131 (34) 156 (148) 639 (604) 203 (141) 176(165) H11 Fig. 1 Biosynthetic cost of AAs is correlated with AA usage in protein sequences. a Proportions of 20 AAs in human proteins. Bar plot on the left shows the biosynthetic cost of each AA (Y20). b The relationship between AA occurrences (log 2 ) in all human protein sequences and cost of AAs (red point, blue triangle and green square for B20, Y20, and H11, respectively). Pearson's correlation test was performed. c Boxplots showing the distribution of Pearson's r for the C-U correlation in seven major taxonomic groups in all domains of life. Phylogenetic tree at left shows the evolutionary relationship between the seven groups. The number of species in each of the seven groups is presented and the number of species showing significant C-U anticorrelation (P < 0.05) is given in parentheses. Due to the conservation of cost metric or food chain, significant C-U anticorrelation was observed in all domains of life with three cost metrics (B20, Y20, and H11). Center line, median; box limits, upper and lower quartiles; whiskers, 1.5 times the interquartile range. d Pearson's r for C-U correlation in animals based on Y20 (x axis) is highly correlated with the corresponding value obtained with B20 (y axis). The red line indicates where y = x. e Correlation between the biosynthetic costs of NEAAs in humans (y axis) against those in yeast (x axis). The nine AAs that can be synthesized from basic metabolites produced during glycolysis and TCA cycle (Ala, Asp, Asn, Arg, Gln, Glu, Gly, Pro, and Ser) are shown in red. The red line shows the results of the linear regression of biosynthetic costs of the nine AAs in humans against those in yeast. Biosynthesis of cysteine (Cys) and tyrosine (Tyr) depends on EAAs methionine and phenylalanine, respectively, and are displayed in gray. A significant correlation was still observed when incorporating Cys and Tyr in the analysis (Pearson's r = 0.79 and P = 0.004 for all 11 NEAAs). f C-U anticorrelation in animals is weaker using H11 metric compared with Y20 metric (Wilcoxon's signed-rank test, P = 3 × 10 −61 33, 34 , as well as in human serum 35 and mouse kidney 34 (Pearson's r ≤ − 0.72, P < 0.05 for B20, Y20, or H11 in each sample; Fig. 2b , Supplementary Fig. 5d ). Therefore, our model suggests that the biosynthetic costs of all 20 AAs constrain the relative abundances of free AAs in human cells, which further shape AA usage in the proteomes by optimizing protein sequences and gene expression levels during evolution (Fig. 2a) . (Fig. 3) . For each gene, we calculated ECPA gene based on its protein sequence and the biosynthetic cost (B20, Y20, or H11) of individual AAs (Fig. 3a) . Due to the difference in AA content, ECPA gene varied considerably from gene to gene (Fig. 3a) , with the genes with lower ECPA gene significantly enriched in the pathways constitutively expressed in the cell types, and the genes with higher ECPA gene significantly enriched in the pathways such as gene regulation (Supplementary Table 4 ). Intriguingly, we detected significant negative correlations between ECPA gene and gene expression levels in each tissue after we grouped the expressed genes into 100 bins with increasing expression levels in that tissue (with Y20 metric, Spearman's ρ ranges from − 0.766 to − 0.345, P < 0.001 in each tissue for mRNA data, and ρ ranges from − 0.622 to − 0.198, P < 0.05 in the tissues, except for fetal gut and platelets for protein data, Fig. 3c and Supplementary Fig. 8 ; see Supplementary Table 5 for results based on B20 and H11). Of (1) NEAAs that are endogenously synthesized in human or other animal cells, which are constrained by H11 cost metric; and (2) AAs ultimately taken from autotrophs, which are constrained by B20 or Y20 cost metric. As a result, the total free AAs show anticorrelation with cost in heterotrophs (H11) or cost in autotrophs (B20 or Y20). Bioavailability of free AAs further shapes AA usage in human proteomes by optimizing compositions of protein sequences and expression levels of genes during evolution. b The relationship between the biosynthetic cost of AAs (B20, Y20, H11) and experimentally measured in vivo concentration of free AAs in mammalian tissues ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06461-1 note, in the above analysis, the correlation between ECPA gene and protein abundance is in general weaker than that between ECPA gene and mRNA abundance ( Fig. 3c and Supplementary  Fig. 8 ), presumably because gene expression measured by mRNA sequencing (mRNA-Seq) is more comprehensive and accurate than the proteomic abundance quantified by mass spectrometry 36 . Overall, our results suggest that the genes highly expressed in human tissues tend to avoid the AAs that would require more energy to synthesize or which are at relatively lower abundance from exogenous supplies.
We extended this analysis to the mRNA expression data of The Cancer Genome Atlas (TCGA) 5 and confirmed similar significant negative correlations in both normal and cancer samples (only cancer types with > 10 matched normal-tumor sample pairs were analyzed; Fig. 3d and Supplementary Fig. 7b for Y20, and Supplementary Table 6 for B20 and H11 results). In 9 of the 15 cancer types surveyed, the negative correlation patterns were significantly stronger in cancer compared with normal tissues (another 4 cancer types showed similar trends, but the differences were not statistically significant; Fig. 3d) . Previous results suggest cancer patients usually have dysregulated AA levels in blood [37] [38] [39] or tumor tissues 40, 41 . However, we observed similar negative correlations between the cost and abundance of the free AAs in tumor and matched normal tissues for a variety of cancer types (Supplementary Fig. 9 and Supplementary Table 7 ). These results suggest that cancer cells may more efficiently manage protein synthesis using the AAs available within their microenvironment.
Consistent prognostic power of ECPA cell across cancer types.
We next questioned whether cancer cells utilize AA for protein synthesis in a way that is more economical than that of normal cells. We analyzed the relationship between ECPA gene and the fold-change in protein abundance in invasive breast carcinoma relative to matched normal samples that were measured with quantitative mass spectrometry in a previous study 42 . After grouping proteins into equal-sized bins based on increasing difference, we found that the change in protein abundance in the tumor relative to normal cells is inversely correlated with ECPA gene for tumors with (Spearman's ρ = − 0.42, P = 0.0023) or without (Spearman's ρ = − 0.32, P = 0.022) lymph node metastasis ( Supplementary Fig. 10 ). These results support the hypothesis that cancer cells utilize AAs for protein synthesis more economically by (1) preferentially downregulating or (2) avoiding upregulating the genes rich in biosynthetically expensive AAs, or by both mechanisms. To more generally study the impact of managing AA usage in various cancer types, we performed a pan-cancer analysis based on ECPA cell (Fig. 3b ) using TCGA mRNA-Seq expression data of 33 cancer types ( Supplementary Fig. 11 ). Of note, ECPA cell , which measures the virtual average cost of proteinogenic AAs in the cells, not only considers the composition of AAs in the protein sequences but also incorporates the gene expression levels. As TCGA mRNA-Seq expression data were quantified at the tissue level, the ECPA cell value represents the average virtual cost of proteinogenic AAs across all the cells present in that sample. We obtained very similar results with the B20, Y20, or H11 cost metric in the analyses. In the following, we primarily focused on the results based on Y20, as it included all 20 AAs. In 11 of the 15 cancer types that have mRNA expression data available for at least 10 normal samples, ECPA cell was significantly lower in tumors than in normal tissues (Fig. 4a) , suggesting that reducing the usage of more expensive AAs in protein synthesis is a general trend for cancer cells. Within a cancer type, the gene expression profiles of different patients are highly heterogeneous. Hence, we analyzed the ECPA cell of tumor samples from different subtypes of breast carcinoma 43 , which has the largest number of samples in TCGA data. Compared with the normal samples, all tumor subtypes have significantly lower ECPA cell ( Supplementary  Fig. 12 ), suggesting that the reduced ECPA cell in cancer cells is robust with respect to tumor subtype. To assess the influence of the heterogeneous cellular composition in the cancer samples 6 , we performed ECPA cell analysis on previously published singlecell RNA sequencing (RNA-Seq) data of melanoma 44 and ovarian carcinoma cells 45 . For both cancer types, the cancer cells have significantly lower ECPA cell values than the immune or stromal cells ( Supplementary Fig. 13 ), suggesting that the reduced ECPA cell in tumors is mainly influenced by the malignant cells rather than the immune and stromal cells within the tumor microenvironment. As the number of AA changes caused by somatic mutations in a cancer sample is small (20~100) 5 , such AA changes have negligible effects on the observed difference in ECPA cell values between the normal and cancer samples. Indeed, we validated this hypothesis by considering the somatic mutations and calculating the ECPA cell values in each tumor sample ( Supplementary Fig. 14) .
To test whether the cancer samples with reduced usage of expensive AAs (i.e., lower ECPA cell ) are more aggressive, we compared the ECPA cell of tumor samples from patients diagnosed at different pathologic stages (from I to IV, see Methods). We found negative correlations between ECPA cell and tumor stage in 16 of the 19 cancer types that have pathological stage information available, 9 of which were statistically significant (Fig. 4b) . We further confirmed significant negative correlations between ECPA cell and pathologic stages in the 9 cancer types (empirical P < 0.05 for each cancer type, Supplementary Fig. 15 ) with permutation tests by shuffling ECPA cell among samples 10,000 times and repeating the correlation analysis (Methods). Therefore, utilizing AAs more economically in protein synthesis confers a greater proliferation advantage upon cancer cells.
Next, we considered whether ECPA cell is associated with patient survival time. Focusing on 17 cancer types with sufficient samples and events (Methods and Supplementary Fig. 11 ), we found that patients with lower ECPA cell showed significantly worse survival probability compared with those with higher ECPA cell in nine cancer types and we did not find a significantly reversed pattern in any cancer type (split by the median ECPA value, log-rank test, Fig. 4c, d ). Further, a lower ECPA cell was significantly associated with poor survival using a univariate Cox proportional hazards model in the nine cancer types. Collectively, in 11 of the 17 cancer types surveyed, lower ECPA cell showed a significant correlation with poorer patient prognosis by either log-rank test or Cox model (see additional cancer types in Supplementary Fig. 11 ). To confirm the statistical significance of the observed pattern, we performed permutation tests on cancer samples and found that the number of cancer types with consistent survival correlation was much higher than the random expectation (at most five in permutations, P < 2 × 10 −4 , Supplementary Fig. 16a ). Importantly, in six cancer types, the Fig. 3 Impact of ECPA gene on the expression of individual genes in normal and cancer tissues. a Schematic diagram showing the calculation of ECPA gene . For each gene, ECPA gene is the average of the biosynthetic cost of AAs weighted by the occurrence of each AA in the protein sequence. ACTB gene is used as an example. The histogram on the right shows the distribution of ECPA gene of 19,571 unique protein-coding genes in humans. b Illustration of ECPA cell calculation with mRNA-Seq data of sample TCGA-AB-2803-03 from TCGA study of acute myeloid leukemia (LAML). ECPA cell is an average of ECPA gene of all expressed genes weighted by lengths regarding encoded AAs and expression levels of those genes. c Correlations between ECPA gene and gene expression level in 12 normal human tissues with both mRNA-Seq and proteomic data available. For each tissue, genes were divided into 100 groups based on their expression levels (spectral count for proteomic data and RPKM for mRNA-Seq), and the median expression level (log 10 ) and median ECPA gene in each group were used in the correlation analysis. Two representative correlations are magnified for more detail. d Correlations between ECPA gene and gene expression level across different cancer (colored) and normal tissues (gray) using TCGA mRNA-Seq data. For each sample of each cancer type, genes were divided into 100 groups based on their expression levels and, the median expression level and median ECPA in each group were used in the correlation analysis. Error bars indicate the 95% confidence intervals of ρ. The number of tumor and normal tissue samples for each cancer type can be found in Supplementary Table 6 . For each cancer type, the significant difference in the correlation coefficient (Spearman's ρ) between tumor and related normal samples is marked as *P < 0.05; **P < 0.01; and ***P < 0. association with ECPA cell remained significant even when the pathologic tumor stage and patient age were considered in the multivariate analysis (Fig. 4c) Fig. 16b ). Indeed, when examining a set of known cancer therapeutic targets or biomarker genes 46 , none of them showed such a consistent prognostic pattern as ECPA cell ( Supplementary  Fig. 16c ). Notably, we also repeated the whole pan-cancer analytical procedures with B20 or H11 and obtained overall patterns that were very similar to those for Y20 ( Supplementary  Figures 17-20) . As tumors often experience hypoxia 47 and thus obtain part of their cellular energy via fermentation 48 , we also repeated the pan-cancer association analysis with anaerobic costs of AAs and found that our conclusions still held ( Supplementary  Figures 21-23 ). Overall, our results indicate that tumors with lower ECPA cell tend to be more aggressive, and patients with such tumors have shorter survival times across a broad range of cancer types. These results also highlight the feasibility of ECPA cell as a potential prognostic marker for patient stratification.
Reduced ECPA in experimental evolution of xenograft tumors. Based on our observations, we argue that lower ECPA cell may be an important feature shaped by natural selection at the systemic and cellular level, and the trend will be enhanced during the evolution of a tumor. To test this hypothesis, we analyzed the data generated in an experimental evolution of xenograft tumors in which an early transformed cell population was first obtained by introducing a mutated oncogene, HRAS V12 , into a normal human breast epithelial cell line (MCF10A) 49 . These MCF10A-HRAS cells were xenografted into mice to form the first-stage xenograft tumor (XT1), the subsequent second-stage xenograft tumor (XT2), then XT3…, until the metastatic tumor was detected in the mouse carrying XT8. The sequential cell samples collected from MCF10A-HRAS, XT1 to XT8, and the two metastatic tumors, XT8_M1 and XT8_M2, represent the full evolutionary process from tumor initiation to metastasis. We analyzed the mRNA-Seq data of the nine primary tumors (Methods) and found that ECPA cell is reduced in the xenograft tumors (XT1 to XT8) compared with the ancestral MCF10A-HRAS cells. Strikingly, we observed a clear decreasing trend of ECPA cell in a temporal order of the eight xenograft tumors (XT1 to XT8) (Pearson's r ≤ − 0.81, P < 0.05 for each cost metric; Fig. 5a ). This in vivo experimental study supports that ECPA cell is selected for reduction during tumor evolution.
To examine the key factors affecting the evolutionary process for managing AA usage, we conducted simulations on the evolution of the ECPA of a single cancer cell population, in which the ECPA cell of the cells varied at a rate of v (per generation). We then sampled them to the next generation based on their fitness values given a selective strength of s (Methods, Fig. 5b and Supplementary Fig. 24 ). We found that higher v and stronger s can lead to a quicker decrease in ECPA cell , whereas the speed of the decrease is largely determined by s (Fig. 5c, d ). We note that the reduction in ECPA cell is not necessarily linearly correlated with the selective advantages in this simulation. Collectively, both our experimental evolution and simulations suggest that reduced ECPA cell is an important feature of tumor cells during cancer progression.
Biological themes related to reduced ECPA cell in tumors. To test whether the reduced ECPA cell in cancer cells occurs by expression level changes of genes of certain pathways or at the genome-wide level, we systematically searched for genes that had expression levels correlated with ECPA cell among the samples for 31 TCGA cancer types that have at least 50 samples available (Methods). As expected, for each cancer type, the positively correlated genes overall have higher ECPA gene , and the negatively correlated genes tend to have lower ECPA gene (Fig. 6a, Supplementary Fig. 25, Supplementary Tables 8 and 9 ). For most cancer types, the positively correlated genes are significantly enriched in the pathways related to the mitochondrion (Fig. 6b , Supplementary Table 10 ). The negatively correlated genes are overrepresented in pathways that tend to have lower ECPA gene compared to the genomic background (Fig. 6c, Supplementary  Table 10 ), and the power of ECPA cell in the pan-cancer analysis was considerably compromised when we excluded these pathways ( Supplementary Fig. 26 and Supplementary Table 11 ). These results suggest that the pathways rich in expensive AAs are not upregulated overall in cancer cells so that expensive AAs are economically used. However, we did not find such patterns for the pathways enriched with positively correlated genes (Supplementary Table 11 ), suggesting that reduced ECPA cell in tumor cells is not the direct consequence of the downregulation of genes in specific pathways.
Tumor suppressors and cancer drivers 4 , as well as genes involved in AA biosynthesis and transport 50, 51 , are often dysregulated in tumor cells. Accordingly, we identified numerous genes in those functional categories that are differentially expressed in tumor cells (Fig. 6d and Supplementary Fig. 27a-d) .
Nevertheless, the dysregulation of these genes is unlikely to predominantly affect ECPA cell in tumors, as they have ECPA gene that is similar to the background level ( Supplementary Fig. 27e) ; and importantly, the results of the overall pan-cancer analysis remain intact after we excluded each category from the analysis (Supplementary Table 11 ). The expression levels of proliferationrelated genes 52 are increased in tumors compared to the matched normal samples (Supplementary Fig. 28a ). Although the proliferation-related genes have lower ECPA gene than the genomic background ( Supplementary Fig. 28b ), the results of pan-cancer analyses are only slightly affected by these genes ( Supplementary Fig. 29 and 30) . Furthermore, the reduction of ECPA cell during experimental evolution of xenograft tumors still holds when the proliferation-related genes were excluded ( Supplementary Fig. 31 ). These results suggest that the association between ECPA cell and cancer progression is unlikely to be caused by changes in proliferation-related genes alone. To test whether cancer cells preferably express proteins with lower total biosynthetic cost, we calculated the total energy cost of each protein (EC gene ) as the sum of the biosynthetic cost of AAs in each protein sequence. As expected, genes with higher EC gene tend to have lower expression levels in both normal tissues and tumors ( Supplementary Fig. 32a ), and be under-represented in the upregulated genes in cancer cells (Supplementary Fig. 32b) . Moreover, the EC cell values, which are calculated as the average EC gene of genes weighted by their expression levels (Methods), are significantly lower in tumors than in normal tissues (Supplementary Fig. 33) . Nevertheless, the pathological stage of tumors or the survival time of patients is generally not associated with the EC cell parameters in the pan-cancer analysis ( Supplementary  Fig. 33 ), suggesting that EC cell is not suitable for a prognostic marker of cancer progression. Taken together, our results suggest that the economical use of AAs in protein synthesis in cancer cells is achieved by (1) avoiding upregulation of pathways enriched for expensive AAs and (2) the cumulative effect of downregulating individual genes that are enriched for expensive AAs. We conclude that the efficient use of AAs in cancer cells is achieved by the coordinated regulation of gene expression at the wholetranscriptome level. Although specific pathways might contribute to this process, none of them is overwhelmingly dominant in this process.
The predictive power of ECPA cell for immunotherapy. Checkpoint inhibitor immunotherapy is one of the most exciting developments in cancer treatment 53 . The expression levels of PD-1 (PDCD1) or PD-L1 (CD274) are associated with the response to checkpoint blockade therapy 54, 55 . Although PD-1 and PD-L1 are usually dysregulated in tumors compared to normal tissue samples ( Supplementary Figs. 34a and 35a) , the expression level of neither gene showed consistent association with the pathological stage of tumors or patient survival time ( Supplementary Fig. 34  and 35 ). We questioned whether ECPA cell can predict response to immunotherapy and hypothesized explicitly that higher ECPA cell is associated with a better clinical outcome. We applied our method to a recent study on anti-PD-1 therapy in metastatic melanoma 56 in which the mRNA-seq data for patient samples are available. Indeed, ECPA cell for patients in the responding group was significantly higher than that of patients in the nonresponding group (one-sided t-test, P = 0.032, Fig. 7a ). By contrast, we did not find significant differences in the expression levels of PD-1 (t-test, P = 0.85) or PD-L1 (t-test, P = 0.49) between patients in the responding group and the nonresponding group, which is consistent with a recent study 57 . These results suggest that tumors with low ECPA cell can survive better than those with high ECPA cell when undergoing a T-cell attack and therefore become more resistant to immunotherapies. To further confirm that the observed significant pattern is due to the biosynthetic costs of different AAs, we randomly permutated the biosynthetic energy costs of AAs 1000 times, repeated the above analysis between the two response groups, and visualized the obtained P-values and ECPA cell differences [log 2 (responding/ non-responding)] using a volcano plot (Fig. 7b) . We found that the ECPA cell difference obtained from using the real biosynthetic energy costs of AAs was significantly larger than that obtained BLCA  BRCA  CESC  COAD  ESCA  GBM  HNSC  KICH  KIRC  KIRP  LAML  LGG  LIHC  LUAD  LUSC  MESO  OV  PAAD  PCPG  PRAD  READ  SARC  SKCM  STAD  TGCT  THCA  THYM  UCEC  UCS  UVM   ECPA Regulation of epithelial to mesenchymal transition AXIN1  DNMT1  EZH2  TP53  DNMT3A  SRSF2  MSH6  RNF43  FUBP1  KRAS  B2M  CTNNB1  IDH2  GATA2  CYLD  BBC3  CHEK1  E2F1  E2F3  EED  AIMP2  ATR  BANP  CDH11  EPHB4  BHLHE41  ARL6IP5  DUSP22  AHCYL1  EPAS1  MTHFD1L  ASNS  CAD  PYCR2  SHMT2  ATIC  ENOPH1  EIF2B4  ALDH18A1  GART  DHFR  MTHFD1  GAMT  GLS  THNSL1  SLC1A4  SLC25A22  PQLC2  SLC38A7  SLC38A1  SLC3A2  SLC6A6  SLC25A15  SLC38A2  SLC38A9  SLC25A12  SLC43A2  SERINC3  PEX3  SERINC1   LIHC  BRCA  LUAD  LUSC  COAD  ESCA  STAD  KICH  THCA Table 8 . Error bars indicate 95% confidence intervals. Wilcoxon's rank-sum tests were performed to compare the ECPA gene of positively or negatively correlated genes and that of the remaining genes (*P < 0.05; **P < 0.01; ***P < 0.001). b Pathways over-represented in positively correlated genes and the distribution of ECPA gene of genes in each pathway (number of genes displayed beside the bar). ECPA gene of positively correlated genes in each pathway compared to genomic background (dashed line) with Wilcoxon rank-sum tests. c Pathways over-represented in negatively correlated genes and the distribution of ECPA gene of genes in each pathway (number of genes displayed beside the bar). ECPA gene of negatively correlated genes in each pathway compared to genomic background (dashed line) with Wilcoxon's rank-sum tests. d Examples showing differential expression of cancer drivers, tumor suppressors and genes related to AA biosynthesis or transport between tumor and normal samples with respect to their ECPA gene in the 11 cancer types that had significantly lower ECPA cell in tumors. Up-or downregulated genes are identified with t-tests at an FDR of 0.05 and displayed in red and blue, respectively. Differential expression events that contribute to the decrease or increase of ECPA cell in tumors are displayed with dark and light color, respectively. Insignificant events are shown in white. For box plots, center line, median; box limits, upper and lower quartiles; whiskers, 1.5 times the interquartile range from using the shuffled energy costs (empirical P = 0.012, Fig. 7b) .
We further examined whether ECPA cell can improve the predictive power of clinical variables in response to immunotherapy using the common machine learning method of random forests 58 with leave-one-out cross-validation (Fig. 7c) . We split the candidate features into four groups: (i) clinical variables (i.e., gender, age, pretreatment, and pathologic stage); (ii) mutation status of three well-known melanoma driver genes (BRAF, NRAS, and NF1); (iii) mutation load; and (iv) ECPA cell . Without ECPA cell , the mutation load alone achieved the best accuracy (0.58) among all the models. After adding ECPA as candidate features into the models, there was significantly improved predictive power across the models (median accuracy 0.69 [with ECPA cell ] vs. 0.42 [without ECPA cell ]; one-sided paired t-test, P = 0.003). The best predictive model was the combination of clinical variables and ECPA cell , with a predictive accuracy of 0.77. These results show that tumors with high ECPA cell are more responsive to anti-PD-1 immunotherapy, and this feature can significantly improve the predictive power of any combination of clinical data, signature genes, and mutation load. Thus, ECPA cell represents a novel, simple, and promising metric for predicting the response to checkpoint inhibitor immunotherapy.
Discussion
Cancer cells employ multiple strategies to acquire AAs 10 , such as the endogenous synthesis of NEAAs 11, 19, 20, 59, 60 , upregulation of AA transport 50, 51, 59 , or through micropinocytosis 61 . Besides protein synthesis, certain AAs, such as asparagine 19, 59, 60 , glycine 20 , glutamine 11, 18, 62 , histidine 63 , leucine 64 , proline 65 , and serine 66 , participate in various cellular processes such as nucleotide synthesis, cellular signaling, and regulation of gene expression 67, 68 . Of note, recent studies have demonstrated that protein synthesis is the cellular process that consumes the most AAs 11 . As the use of all 20 AAs in human proteomes is constrained by their synthetic costs in living organisms, our ECPA concept effectively reflects how cancer cells optimize gene expression profiles for AA usage adaptation. We revealed a common principle governing cancer evolution: cancer cells evolve to use AAs more economically by downregulating genes that are rich in costly AAs. This trend is evident through the comparison between tumor and normal tissue samples, the within-disease 
Responding (14) a b c Fig. 7 The predictive power of ECPA cell for response to anti-PD-1 immunotherapy. a Comparison of ECPA cell between responding (14 patients) and nonresponding (12 patients) groups diagnosed with melanoma. One-sided t-test P-value is shown. Center line, median; box limits, upper and lower quartiles; whiskers, 1.5 times the interquartile range. b Volcano plots showing how P-values and ECPA cell differences (responding/non-responding) for the two-group comparison of ECPA cell are distributed given 1000 permutations, where the biosynthetic energy costs of 20 AAs were randomly shuffled. The gray horizontal and vertical lines indicate the P-value and the fold-change observed from the true ECPA cell . The red dots falling in the upper-right corner of the gray lines represent random cases that are better than the true values shown in a. Empirical P-value (P = 0.02) was estimated using the number of red dots divided by the total number of permutation tests. c Comparison of predictive power between the models with and without ECPA cell using random forests with leave-one-out cross-validation. In addition to ECPA cell (purple circle), three groups of candidate features were used: clinical variables (red circle), mutation status of melanoma driver genes (yellow circle) and mutation load (green circle). The P-value (0.003) was calculated by paired t-test between the models with and without ECPA cell as the candidate feature. The paired models are linked by the solid gray lines analysis across a diversity of cancer types, and the in vivo experimental evolution of a xenograft tumor. Thus, our study provides novel insights into how efficient usage of AAs benefits cancer cells from an evolutionary perspective and at the systemic level. Moreover, the ECPA cell metric we developed shows good prognostic power (compared to individual genes) across many cancer types and can also help predict the tumor response to anti-PD-1 therapy for patients with metastatic melanoma. As the ECPA cell metric is designed to quantify the usage of AAs in protein synthesis based on their biosynthetic costs, by definition the most appropriate approach for calculating ECPA cell should be the rate of protein synthesis. In this study, we calculated ECPA cell using RNA-Seq data, as recent studies based on ribosome profiling have demonstrated a high correlation between mRNA and the rate of protein synthesis 69 . To further validate our analysis, we retrieved the ribosome profiling data of normal (n = 6) and tumor (n = 10) samples of human kidney tissue 65 and calculated ECPA cell with the ribosome-protected fragments (Supplementary Methods). Consistent with the observation using TCGA mRNA-Seq data, we found that ECPA cell in the tumor samples is significantly lower than that in the normal samples whenever we used the Y20, B20 or H11 metric ( Supplementary  Fig. 36 ). Hence, our ECPA analysis based on mRNA-Seq data provides a simple and powerful method that informs how economically AAs are utilized during cancer evolution.
Conceptually, our ECPA study is fundamentally novel to the field and represents a substantive departure from the status quo, namely, gene-based analyses. We emphasize the management of the overall AA expenditures by summarizing the effects of all the genes in the cell, because individual changes that accumulate at the systemic level collectively define the cellular properties that are evident through natural selection in tumor evolution. From this point of view, our study emphasizes the importance of holism in understanding cancer evolution and improving cancer medicine.
Methods
Biosynthetic energy costs of AAs. The biosynthetic cost of each AA, C i (i = 1 to 20), measured by the number of high-energy phosphate bonds required for synthesis, was obtained from previous studies in bacteria 22 and yeast 21, 26 . The detailed procedures for calculating the biosynthetic cost for each of the 11 NEAAs in humans (H11) are presented in Supplementary Figures 1-3 and the Supplementary Methods. For each biosynthetic cost metric (B20, Y20, or H11), the decay rate-normalized biosynthetic cost of an AA, W i (i = 1 to 20 for B20 and Y20, and i = 1 to 11 for H11), was calculated as the product of the biosynthetic cost and the decay rate for each AA, i.e., W i = C i ·D i (i = 1 to 20 for B20 and Y20, and i = 1 to 11 for H11), as described previously 23 .
The anaerobic biosynthetic cost of AAs in yeast was obtained from previous studies 21, 26 . The anaerobic biosynthetic cost of AAs in bacteria or humans was calculated by counting only the number of high-energy phosphate bonds that are directly consumed or produced during AA biosynthesis as performed previously 26 . The decay rate-normalized anaerobic cost of AAs in yeast, bacteria or humans was calculated as described above.
The C-U correlation analysis based on protein sequences. All the protein sequences in seven taxonomic divisions (archaea, bacteria, protists, plants, fungi, invertebrates, and vertebrates) annotated in the Swiss-Prot and TrEMBL databases were downloaded from the UniProt website (www.uniprot.org). Species with more than 500 unique protein sequences were analyzed. In each species, Pearson's r between the occurrence of AAs (log 2 ) and the cost of AAs (B20, Y20, or H11) was calculated. We performed permutation tests by randomly shuffling the cost of AAs (B20, Y20, or H11) 10,000 times and repeating the correlation analysis in Escherichia coli, Saccharomyces cerevisiae, Arabidopsis thaliana, Drosophila melanogaster, Mus musculus, and humans.
The relationship between in vivo concentrations and biosynthetic costs of AAs. The in vivo concentrations of AAs hydrolyzed from proteins of bacteria, yeast, and whole bodies of different animals ( Supplementary Fig. 5 ), as well as the in vivo concentrations of free AAs in tissues/blood of humans and other mammals (Fig. 2a) , were extracted from previous studies and are summarized in Supplementary Table 12 . For each sample, Pearson's r between the concentrations (log 2 ) and cost (log 2 ) of AAs (B20, Y20, or H11) was calculated. We also performed permutation tests by randomly shuffling the costs of AAs (B20, Y20, or H11) 10,000 times and repeating the correlation analysis in each sample. 
where N i is the number of the AA i in the protein sequence of that gene (k = 20 for B20 and Y20, and k = 11 for H11). The total energy cost of AAs in a protein sequence was thus calculated as
The ECPA for a sample, ECPA cell , was calculated with the 73 .
We assessed the association of ECPA with pathological stage using Spearman's rank correlation. The survival time of patients used in the analysis was the number of days until death or until the last follow-up for patients who were still alive at the time of censoring. We assessed the association of ECPA cell with patient survival times using log-rank tests (patients were split into two groups based on the median ECPA cell value) or the univariate Cox proportional hazards model with the survival package 74 . We performed the analysis in 33 cancer types. Due to the limited sample size and shorter follow-up time, the analysis for some cancer cohorts might have had low statistical power to detect significant correlations. Therefore, we focused on 17 cancer types that had ≥ 75 cases and ≥ 25% events (Fig. 4c, d , Supplementary  Fig. 14c and Supplementary Fig. 15c ). We used multivariable Cox proportional models (survival~stage + ECPA, survival~age + stage + ECPA) to assess the additional prognostic power of ECPA cell . To evaluate statistical significance, we randomly shuffled the sample labels within each cancer type 1000 times and repeated the analyses to infer the background distribution. The significance of the observed cancer types associated with patient survival (P < 0.05 in the log-rank test or univariate Cox model or in both tests with the same direction) was calculated based on the background distribution. We performed a similar analysis by stratifying patients based on the expression level of each gene. Besides using all the expressed genes, we focused on only the therapeutic targets or biomarker genes 46 .
All the analyses mentioned above were performed with the Y20, B20, and H11 metrics separately.
Analysis of single-cell RNA-Seq data. The processed single-cell RNA-Seq data and the classification of cell types were obtained from Gene Expression Omnibus (GEO) under accession GSE72056 for the melanoma dataset 44 and from figshare (figshare.com/s/711d3fb2bd3288c8483a) for the ovarian cancer ascites dataset 45 . For both datasets, the gene expression levels of each cell were quantified as transcript per million by the original studies and directly used to compute ECPA cell values. The differences in ECPA cell between different cell types in each dataset were compared with Wilcoxon's rank-sum tests.
Analysis of experimental evolution of xenograft tumor. The experimental evolution of xenograft tumor was described previously 49 . For MCF10A-HRAS, XT1, XT2, XT3, XT4, XT5, XT6, XT7, and XT8, and the two metastatic tumors, XT8_M1 and XT8_M2, the Poly(A) + mRNA sequences were downloaded from the Sequence Read Archive (accession number PRJNA268433). Based on the gene RPKM values, we calculated ECPA cell values for the nine primary tumor samples and conducted linear regression of ECPA cell against the generation number of the eight derived primary tumor samples (XT1 to XT8).
Computational simulation of ECPA-based cancer cell evolution. The evolution of the cancer cell population was simulated with an initial population size N(0) = 10,000 cells. The growth of the population follows a Gompertz growth function so that the population size at generation g is N g ð Þ ¼ N 0 ð Þ Á e α β 1Àe
, where α is the initial proliferation rate and β is the rate of exponential decay of this proliferation rate. The experimentally fitted parameters are α = 0.56 and β = 0.0719 for cancer cell growth per day 75 . The growth time (day) was converted to the number of generations in this study (22 h for a cell cycle duration).
The initial ECPA for each cell was set to 143 (based on the mean ECPA cell of all the TCGA samples), and the optimal ECPA was arbitrarily set at 140 based on the bottom 10% quantile of ECPA cell for all the TCGA samples (we also used other quantile values and observed similar patterns). At each generation, the fitness (f) of a cell is f ¼ e The cell population in generation g was sampled to generation g + 1 based on cellular fitness given a selective coefficient s. In each generation, the ECPA of a cell k, ECPA g,k has a probability v (10 −6 -10 −2 ) of mutating to a value ECPA' g,k . ECPA' g,k follows a gamma distribution with mean equal to ECPA g,k and variance equal to 3.12 (calculated based on ECPA of all TCGA samples, except for liver cancer because the ECPA of these samples is much higher than that of the others). Each simulation process was replicated 200 times.
Analysis of gene categories dysregulated in tumors. The list of cancer driver genes was taken from Vogelstein et al 4 ., and the list of tumor suppressors was from TSGene database (https://bioinfo.uth.edu/TSGene/). Annotation for genes related to AA biosynthesis and transport was downloaded from Molecular Signature Database GO gene sets (http://software.broadinstitute.org/gsea/msigdb/). The list of 530 proliferation-related genes whose expression are significantly positively associated with growth rates was obtained from Waldman et al. 52 . For each cancer type that has at least ten normal samples in TCGA datasets, the normalized counts (or normalized RPKM for LAML and STAD) of genes were averaged for tumor samples and normal tissue samples, respectively. Genes with average RPKM < 1 (for STAD and LAML) or average normalized read count < 20 (for other cancer types) in tumor or normal tissue samples were excluded. Wilcoxon's signed-rank tests were conducted to test whether there is a significant difference in the mean expression levels of genes in each of the four categories (cancer driver genes, tumor suppressors, and genes related to AA biosynthesis or transport) between tumor and normal tissue samples in this cancer type. We also excluded genes in each of the four categories and repeated the pan-cancer analysis of ECPA with the remaining genes.
Analysis of genes and pathways correlated with ECPA. To identify pathways enriched in genes with high ECPA gene or low ECPA gene , we ranked all the human protein-coding genes based on decreasing ECPA gene and performed gene-set enrichment analyses for the top 6000 genes with highest ECPA gene or the bottom 6000 genes with lowest ECPA gene using DAVID (https://david.ncifcrf.gov/).
To identify genes whose expression levels were associated with ECPA cell , we calculated Spearman's rank correlation between ECPA cell and the normalized expression level of each gene in each of the 31 cancer types that have at least 50 samples available. In each cancer type, genes with normalized read count < 20 were excluded from the correlation analysis. Many positively or negatively correlated genes (false discovery rate-adjusted P-value < 0.05) are presented in Supplementary Table 8 . To identify the gene sets over-represented in positively or negatively correlated genes, we focused on the 20 cancer types that have lower ECPA cell in tumors or have ECPA cell associated with the pathological stage of tumors or patient survival time (Fig. 4) , and performed gene-set enrichment analysis with DAVID for genes that had expression levels that correlated with ECPA cell among samples in the same direction in at least 9 of the 20 cancer types. Positively correlated genes and negatively correlated genes were analyzed separately. Wilcoxon's rank-sum tests were conducted to compare the ECPA gene of positively or negatively correlated genes in each over-represented pathway to that of the genomic background.
Analysis of ECPA with tumor response in anti-PD-1 treatment. We obtained the patients' treatment response data and the normalized gene expression data from Hugo et al. 56 . We used a one-sided t-test to assess whether the ECPA cell values of the responding group were significantly higher than those of the nonresponding group. To further assess the statistical significance of the observed ECPA cell difference, we shuffled the biosynthetic costs of 20 AAs 1000 times and repeated the analysis. The empirical P-value of the true ECPA cell difference was calculated by the number of permutations with a more significant P-value and a larger fold difference in ECPA cell (responding/non-responding) than the true observation. To examine whether ECPA cell can improve the predictive power of clinical variables, we performed model construction using random forests 58 with leave-one-out cross-validation. We considered four groups of candidate features: (i) clinical variables (gender, age, pretreatment, and pathologic stage); (ii) mutation status of the three melanoma driver genes (BRAF, NRAS, and NF1); (iii) mutation load (the number of non-synonymous mutations per patient); and (iv) ECPA cell . We first built models using each of the first three feature sets or their combination and then included ECPA cell as an additional feature. We examined the improvement in predictive power between models with and without ECPA cell using a paired t-test.
Processing of ribosome profiling data. The ribosome profiling data for kidney tumors (six samples of normal and ten samples of tumor kidney tissues) was downloaded from GEO under accession GSE59821 65 . The next-generation sequencing reads were mapped to hg19 using hisat2 (https://ccb.jhu.edu/software/ hisat2/index.shtml) based on the genome annotation from ENSEMBL (www. ensembl.org). In each sample, the reads mapped to coding sequence (CDS) region of protein-coding genes were counted using HTSeq-count (https://github.com/ simon-anders/htseq) with the parameter "-i gene_id -t CDS", and the RPKM value for each gene was calculated as n/L/N × 10 9 , where n is total reads uniquely mapped to CDS region of that gene, L (nt) is the CDS length of longest transcript of that gene, and N is the total number of reads uniquely mapped to protein-coding genes in this library.
